Role of CD1d- and MR1-Restricted T Cells in Asthma

Chiaki Iwamura and Toshinori Nakayama

Innate T lymphocytes are a group of relatively recently identified T cells that are not involved in either innate or adaptive immunity. Unlike conventional T cells, most innate T lymphocytes express invariant T cell receptor to recognize exogenous non-peptide antigens presented by a family of non-polymorphic MHC class I-related molecules, such as CD1d and MHC-related molecule-1 (MR1). Invariant natural killer T (iNKT) cells and mucosal-associated invariant T (MAIT) cells quickly respond to the antigens bound to CD1d and MR1 molecules, respectively, and immediately exert effector functions by secreting various cytokines and granules. This review describes the detrimental and beneficial roles of iNKT cells in animal models of asthma and in human asthmatic patients and also addresses the mechanisms through which iNKT cells are activated by environmental or extracellular factors. We also discuss the potential for therapeutic interventions of asthma by specific antibodies against NKT cells. Furthermore, we summarize the recent reports on the role of MAIT cells in allergic diseases.

Keywords: CD1d, MR1, asthma, invariant NKT (iNKT) cells, mucosal-associated invariant T (MAIT) cells

INTRODUCTION

Innate-like T cells (CD1-restricted T cells or MHC-related molecule-1 (MR1)-restricted T cells) are classified as innate lymphoid cells that have features similar to those of the cells involved in acquired immunity, such as T cell receptor (TCR) expression (1). However, their TCR repertoire is very limited, and they recognize self or exogenous non-peptide antigens presented by a family of non-polymorphic and MHC class I-related molecules (1).

NKT cells are characterized by the expression of TCRs with a limited repertoire, consisting of Vα14 and Jα18 (in mice) or Vα24 and Jα18 (in humans) (2). In addition, their sets of Vβs are also skewed toward mainly Vβ8.2 (in mice) and Vβ11 (in humans). Since NKT cells have limited TCRs, they are called invariant natural killer T (iNKT) cells. α-galactosylceramide (α-GalCer) presented by CD1d is the most potent and well-analyzed ligand that activates iNKT cells (2). Activated iNKT cells regulate various immune responses to protect us from tumors or infectious diseases (3, 4). However, these cells can also contribute to chronic inflammatory disease, such as allergic inflammation and autoimmune responses (5, 6).

Like iNKT cells, mucosal-associated invariant T (MAIT) cells express a semi-invariant TCR with a unique TCRα chain (Vα19-Jα33 in mice, Vα7.2-Jα33 in humans) and a restricted set of TCRβ chains (7). MAIT cells are activated by a bacterial riboflavin derivative presented by MR1 (8). Although MAIT cells have been suggested to play a role in antibacterial immunity through sensing MR-1-bound microbial products, it has been speculated that these cells may also be involved in regulating beneficial host commensal interactions in the intestine and potentially in the lung (9, 10). As well as participating in antimicrobial immunity, MAIT cells may be involved in the control of chronic inflammation (11).
Another interesting feature of these MAIT and iNKT cell populations is their memory-like phenotype (12). They are able to produce effector cytokines, cytotoxic molecules, and growth factors at early time points of immune responses. Therefore, they are considered to play an essential role in the host defense immune responses. Both populations have distinct and characteristic tissue localization, as NKT cells reside in the thymus, spleen, lung and liver, while MAIT cells are preferentially found in the gut lamina propria, lung and liver (13, 14). NKT cells are relatively abundant in mice and show a lower frequency in humans, whereas the opposite situation is true for MAIT cells (15).

Upon activation, iNKT cells produce a large amount of both Th1 and Th2 cytokines in addition to inflammatory cytokines, such as interleukin (IL)-17 and tumor necrosis factor α (TNFα). iNKT cells show heterogeneity in their transcriptional factors. Three different subsets of iNKT cells have been shown to produce distinct cytokines, defined as NKT1, NKT2 and NKT17 (16, 17). iNKT cells are also distinguished by their surface molecules, such as CD4 and IL-17RB. CD4+IL-17RB+ iNKT cells in particular produce IL-13, IL-9, IL-10, IL-17A, and IL-22 (18). Since these cytokines exert different immunoregulatory functions, certain populations of iNKT cells might contribute to the development of chronic disorders, such as allergic diseases (18). MAIT cells produce IFN-γ, IL-4, IL-17, and TNFα (12, 19). Lepore et al. suggested that IL-5 and IL-13 can be produced by MAIT clones (20). It would be possible to identify distinct subsets of MAIT cells, that can produce specific cytokines such as is observed in the case of iNKT cells.

Asthma is a chronic inflammatory disease in the lung that causes recurring periods of wheezing, chest tightness, shortness of breath and coughing. It is well established that allergic asthma is induced by Th2 cell-mediated immune responses (21). Studies by our group and other authors have revealed that chronic airway inflammation in asthma patients is caused by pathogenic memory Th2 cells, which express high levels of IL-33 receptor ST2 and have a CD161highCRTH2high phenotype in human (22–25).

Memory T cells are considered to play a beneficial role by responding immediately and strongly to the secondary invasion by the same antigen of a microorganism (26). However, memory T cells can induce adverse effects in cases of chronic inflammatory disease if they respond to allergens or self-antigens repeatedly for a long duration (27). Thus, allergen-specific memory Th2 cells, particularly the pathogenic subpopulation of ST2+ Th2 cells paly important roles in the pathogenesis of IL-5-induced eosinophilic inflammation and fibrotic responses (24, 28). However, it is also recognized that asthmatic patients show heterogeneous phenotypes, including so-called type-1 and type-2 mixed inflammation with neutrophilic infiltration. Thus, other cell types, such as NKT cells likely contribute to the development or exacerbation of asthma (29).

This review describes and discusses the immunoregulatory roles of innate-like T cells in asthma in animal models and human patients.

**BENEFICIAL AND DETRIMENTAL EFFECTS OF iNKT CELLS FOR ALLERGIC ASTHMA**

Many investigators have tried to determine the roles of iNKT cells in asthma over the past 20 years. To this end, Akbari et al. assessed OVA-induced airway hyperactivity (AHR) and allergic airway inflammation in iNKT cell-deficient Jo281 knockout (KO) and CD1d KO mice (30). They noted a significant defect in the development of AHR and inflammation in these NKT cell deficient mice. The defects were corrected by the adoptive transfer of iNKT cells in an IL-4- and IL-13-dependent manner. Therefore, iNKT cells were considered to contribute to the development of AHR and airway inflammation independent of Th2 cells. In addition, the same group showed that non-classical NKT cells, which are restricted to a β2-microglobulin-independent form of CD1d, also contribute to the development of AHR (31). Woo et al. further suggested that iNKT cells are also required for the generation of Th2 cells by recruiting CD103+ dendritic cells (DCs) to the lung via the XCL1-XCR1 axis (32). Furthermore, another group suggested that iNKT cells act as an adjuvant to enhance allergic asthma, as systemic iNKT cell activation by α-GalCer administration or adoptive transfer of iNKT cells before OVA challenge significantly augmented the Th2 inflammatory responses (33). These results indicate that iNKT cells have detrimental effects in allergic asthma.

Simultaneously, other groups reported experimental results indicating that iNKT cells are not involved in the development of allergic asthma. OVA-induced allergic inflammation was not reduced in CD1d-deficient mice or β2-microgloblin KO mice lacking iNKT cells (34, 35). Moreover, a protective role of iNKT cells in allergic asthma was suggested. Subsequent AHR in these models can be suppressed by the systemic activation of iNKT cells by α-GalCer treatment or the transfer of α-GalCer-loaded bone marrow-derived DCs before OVA challenge in an IFN-γ-dependent manner (36, 37). In addition, Grela et al. reported that IFN-γ-producing iNKT cells stimulated with toll like receptor (TLR) 7 agonist (R848) attenuated allergic asthma, which is consistent with the finding that TLR7 stimulation not only enhances viral responses but also alleviates experimental asthma (38).

Thus, iNKT cells display either beneficial or detrimental effects in allergic asthma. These conflicting effects may be due to the various cytokine production patterns of iNKT cells under different conditions. IL-4 or IL-13 production from iNKT cells is required for the development of allergic asthma in mouse models, while iNKT cells can produce IFN-γ, which can suppress the Th2 response and thereby prevent allergic asthma. However, even when employing similar protocols, different institutes obtained completely different findings (33, 36, 37). Since iNKT cells can detect bacterial components through their invariant TCRs or

**Abbreviations:** MR1, MHC-related molecule-1; TCR, T cell receptor; iNKT, invariant natural killer T; α-GalCer, α-galactosylceramide; MAIT, mucosal-associated invariant T; IL, interleukin; TNFα, tumor necrosis factor α; AHR, airway hyperactivity; KO, knockout; TLR, toll like receptor; Myl, myosin light chain; HDE, house dust extract; TIM-1, T cell immunoglobulin and mucin domain-1; PtdSer, phosphatidylserine; TSLP, thymic stromal lymphoprotein; DCs, dendritic cells; BALF, bronchoalveolar lavage fluid.
Toll-like receptors, the difference in the lung microbiota may affect the function of distinct iNKT cell subsets, such as NKT1 and NKT2.

Although inducing Th1 bias by iNKT cell activation may result in the inhibition of AHR and eosinophilic infiltration, our recent study shed light on how NKT cell activation can suppress Th2 type inflammation. While immunological memory plays a central role in providing protection against infection or cancer, antigen-specific memory CD4 T cells contribute to the pathogenesis of allergic and autoimmune disorders by recognizing allergens or self-antigens (24, 39). Our data showed that the activation of iNKT cells with α-GalCer during the memory phase resulted in the downregulation of IL-4, IL-5, and IL-13 and up-regulation of IFN-γ in memory Th2 cells (40). These functionally altered memory Th2 cells display a decreased capability to induce Th2 cytokines and eosinophilic airway inflammation. We therefore concluded that activated iNKT cells directly regulate memory Th2 cell function in vivo. Chang et al. showed another inhibitory mechanism for allergic disorder by iNKT cells. They found that influenza infection in neonates helped prevent allergic asthma by inducing CD4αβ+CD8αβ+ iNKT cell activation, which is associated with the expansion of regulatory T cells (41). The inhibitory effect required T-bet and TLR7 expression in iNKT cells. Furthermore, the administration of α-GalCer or glycolipid derived from Helicobacter pylori to neonates recapitulated the result (41), suggesting that infection with certain microorganisms can prevent the subsequent development of allergic asthma by expanding a specific subset of iNKT cells. Therefore, the authors proposed that treatment of children or allergic patients with compounds such as α-GalCer or other glycolipids derived from microorganisms might be effective in preventing or improving the development or symptoms of allergic asthma.

LUNG iNKT CELL-DEPENDENT ALLERGIC OR NON-ALLERGIC ASTHMA

Lung iNKT cells are relatively abundant compared to iNKT cells in the peripheral blood (14). The activation of pulmonary iNKT cells by the intranasal α-GalCer administration rapidly induced AHR and eosinophilic inflammation in naïve mice, and this effect was independent of conventional CD4 T cells (42). Michel et al. showed that NK1.1+ αβ+ iNKT cells produced high levels of IL-17 and induced neutrophilic infiltration following the intranasal administration of α-GalCer in a murine model (43). In addition, the development of AHR was observed in non-human primates by the direct activation of pulmonary iNKT cells with α-GalCer, indicating that pulmonary iNKT cells are critical effector cells in these animal models (44). Our previous study showed that α-GalCer induced AHR and neutrophilic infiltration, and the neutrophilic infiltration was significantly attenuated in CD69-deficient mice, indicating that activated iNKT cells-mediated asthmatic responses were dependent on CD69 expression (5). We recently identified myosin light chain (Myl) 9 and Myl12 as functional ligands for CD69 (45). We also showed that the interaction between CD69 on Th2 cells and Myl9 expressed on the luminal side of endothelial cells in the blood vessels recruits activated Th2 cells to the inflammatory site, resulting in airway inflammation (45, 46). CD69 on iNKT cells might therefore induce the migration of iNKT cells to the lung by binding to Myl9 or Myl12 and also play a critical role in the development of AHR and airway inflammation (Figure 1).

Even if iNKT cell activation in the lung does contribute to asthma, we are unlikely to be exposed to α-GalCer, a component of marine sponge, in our daily lives. Several studies have indicated that substances naturally existing in our environment, such as allergens, pathogens and air pollution, might activate iNKT cells and cause or exacerbate airway inflammation. Glycolipids from bacteria, such as Sphingomonas, Borrelia, and Leishmania species, are recognized by invariant TCR of iNKT cells (47). In particular, glycolipids purified from Sphingomonas cell walls were shown to induce rapid AHR after respiratory administration in wild-type mice but not iNKT-deficient mice (42). Although a glycolipid that can induce iNKT cell activation has not been identified in viruses, Kim et al. suggested that viruses may facilitate CD1d antigen presentation and induce iNKT cell activation in an indirect manner (48). The authors also showed that IL-13 production from macrophages stimulated by iNKT cells during respiratory virus infection induces the development of AHR and mucus production independent of the adaptive immune response. Aspergillus fumigatus is a saprophytic fungus that is ubiquitous in the environment and is commonly associated with allergic asthma (49). Albacker et al. reported that the Aspergillus fumigatus-derived glycosphingolipid asperamide B directly activates iNKT cells in a CD1d-restricted, Myd88-independent, and dectin-1-independent manner (50). The intranasal administration of asperamide B rapidly induced AHR and neutrophil infiltration into the lung, suggesting that fungi can contribute to the induction of asthmatic symptoms by iNKT cells. Therefore, iNKT cells activated by glycolipids from microorganisms may contribute to the development and exacerbation of asthma symptoms in humans.

It was recently revealed that non-glycolipid stimulation could also activate iNKT cells, resulting in the induction of AHR. House dust extract (HDE) contains antigens and is capable of inducing airway inflammation by activating mouse Vα14 or human Vα24 NKT cells (51). The stimulation of mouse Vα14 iNKT cells was shown to be CD1d-dependent and not dependent on TLR agonist present in HDE. Although the antigen in HDE remains incompletely characterized, the authors suggested that the immunostimulatory material in HDE was of neither bacteria nor glycolipid origin (51). Ozone is an air pollutant that has also been reported to be associated with asthma (52, 53). The development of AHR was found to be inducible even in healthy individuals following exposure to ozone, which causes airway epithelial damage, and increased numbers of neutrophils (54, 55). Furthermore, asthmatic patients are more susceptible to the detrimental effects of this pollutant. A murine model of ozone induced-asthma revealed the indispensable role of IL-17-producing iNKT cells for the induction of AHR (56). Although how ozone activates iNKT cells is unclear at present, NKT cells activated by ozone can induce a form of asthma that is characterized by cellular infiltration and AHR.
In addition to the naturally existing molecules in the environment, extracellular factors are also known to activate iNKT cells. T cell immunoglobulin and mucin domain-1 (TIM-1) is an important asthma susceptibility gene and also a receptor for phosphatidylserine (PtdSer) (57), an important marker of cells undergoing programmed cell death or apoptosis (58). NKT cells can activate, proliferate, and produce cytokines through recognition of PtdSer by TIM-1 (59). Furthermore, the apoptosis of airway epithelial cells activates pulmonary NKT cells, resulting in AHR and suggesting that TIM-1 serves as a pattern recognition receptor on NKT cells that senses PtdSer on apoptotic cells as a damage-associated molecular pattern (60). Previous studies have shown that apoptosis induced by virus infection or ozone exposure can trigger NKT activation (48, 56, 60), as infection with some viruses triggers apoptosis and externalization of PtdSer. In addition, it has been reported that TLR signaling enhances the activation of iNKT cells. Vultaggio et al. showed that systemic dsRNA (poly(I:C)) selectively upregulates the IL-17 production from iNKT cells activated by α-GalCer. The authors therefore expected that the exacerbation of airway inflammation might be induced by certain virus infections (61). Furthermore, several cytokines involved in the initiation and amplification of Th2 responses have been reported (62). IL-25 is capable of enhancing AHR and is produced by activated Th2 cells, epithelial cells, basophils, and mast cells (63). The administration of recombinant IL-25 induced Th2-type responses, including increased serum IgE levels, eosinophilia, pathological changes in the lung, and AHR. These symptoms induced by IL-25 were not observed in iNKT cell-deficient mice (64, 65). Moreover, iNKT cells expressing IL-17 receptor B were shown to be essential for IL-25-induced AHR using an adoptive transfer model (65). Thymic stromal lymphoprotein (TSLP) is also considered to play
an important role in the iNKT cell-dependent asthma model (66). While the targets of TSLP are T cells, mast cells, basophils, and DCs, Nagata et al. demonstrated that TSLP also acts on iNKT cells to enhance AHR by up-regulating their production of IL-13 (67). IL-33 enhanced the production of Th1 and Th2 cytokines in activated NKT cells (68, 69). These results indicate that natural ligands in the environments act as antigens for iNKT cells to induce allergic asthma, and TCR-independent stimuli to iNKT cells may exacerbate the asthmatic symptoms such as AHR (Figure 1).

Although it is obvious that the direct activation of lung iNKT cells causes lung inflammation, which types of inflammation are induced is still controversial. Two groups claimed that the intranasal administration of α-GalCer induced allergic airway inflammation because eosinophil infiltration into the lung, a feature of type 2-mediated responses, was observed in IL-4- and IL-13-dependent manners (42, 70, 71). However, neutrophil infiltration, which represents non-allergic airway inflammation, is frequently observed in severe or Th17-mediated asthma (72, 73). The activation of iNKT cells by the intranasal administration of α-GalCer, asperamide B or PtdSer induces pulmonary neutrophil infiltration, suggesting that iNKT cell may contribute to non-allergic airway inflammation (5, 43, 50, 59). In contrast, equivalent numbers of eosinophils and neutrophils have been noted with ozone or poly (I:C) stimulation (56, 61). This discrepancy in outcomes may be due to the activation of distinct subsets of iNKT cells: one produces IL-13 and IL-5, which activate and recruit eosinophils; the other produces IL-17, thereby inducing the recruitment of neutrophils. Additional flow cytometry single cell analyses addressing the precise production profiles of cytokines in iNKT cells are needed in order to discriminate the infiltrated subsets.

With many clinical and experimental examinations, it has been revealed that asthma is more heterogeneous and complex than previously thought. While allergic asthma is induced by allergens and mediated by Th2 cells, a non-allergic form of asthma is caused independent of Th2 responses (29). Non-allergic asthma is induced by multiple environmental factors, such as air pollution (smoke, ozone, and diesel particles) and virus infection. Although the immunopathological pathways of non-allergy asthma are still unclear, the activation of iNKT cells with their specific ligands or cytokines may contribute to the development of non-allergy asthma.

Taken together, these findings suggest that different types of iNKT cell ligands may activate distinct subsets of iNKT cells, thereby resulting in distinct patterns of airway inflammation. Therefore, lung iNKT cell activation may contribute to the development of various types of asthmatic inflammation (Figure 1).

**THERAPEUTIC INTERVENTION FOR iNKT CELL-DEPENDENT ALLERGIC ASTHMA**

As we pointed out above, iNKT cells may play a critical role in the development or exacerbation of asthma. Although further investigations are needed, Dimaprit (H2 histamine receptor agonist) or intravenous immunoglobulin treatment does appear to suppress iNKT cell-dependent allergic asthma (74, 75). The administration of anti-mouse CD1d monoclonal antibodies (20H2) or CD1d-dependent antagonist has also been shown to suppress OVA-induced AHR and inflammation in murine models (76, 77). Indeed, McKnight et al. reported that anti-mouse CD1d monoclonal antibody (20H2) treatment before the intranasal administration of α-GalCer impaired iNKT cell-induced AHR in an experimental mouse model of asthma, while this antibody did not suppressed OVA-induced allergic asthma. These results suggest that this antibody may attenuate non-allergic asthma (35). Anti-human CD1d antibody (NIB.2) possesses a high affinity for human and cynomolgus macaque CD1d and inhibits NKT cell activation by inhibiting the interactions of the TCRβ chain of iNKT cells with CD1d (78). NIB.2 treatment significantly reduced the cytokine levels and numbers of lymphocytes and macrophages in the bronchoalveolar lavage fluid (BALF) in a primate model of asthma (78). However, this antibody may affect other CD1d-restricted T cells that are not involved in airway inflammation (79). Therefore, the development of a more specific method will pave the way for therapeutic interventions to alleviate symptoms.

Mouse invariant monoclonal antibody, NKT14 was found to specifically bind to invariant TCR of mouse iNKT cells and deplete iNKT cells in mice via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity for 3 weeks (80). The elimination of iNKT cells was sufficient to prevent murine AHR and pulmonary eosinophilic inflammation elicited by the oropharyngeal inhalation with α-GalCer (71). In addition, NKT14 administration prior to sensitization abrogated either antigen-mediated AHR alone or both AHR and pulmonary inflammation (71, 80).

**ROLE OF iNKT CELLS IN ASTHMA PATIENTS**

In order to determine the role of iNKT cells in human asthma, many investigators have examined iNKT cells in asthma patients with regard to their numbers and the production of cytokines (Table 1). An initial report published in 2006 by Akbari et al. stated that more than 60% of CD4 T cells in the BALF from severe asthmatic patients were iNKT cells, while the infiltration of iNKT cells was not observed in patients with other pulmonary diseases, such as sarcoidosis, or in healthy controls (81). Three other supportive reports showed that asthmatic patients display higher frequency of iNKT cells in BALF as compared to healthy control donors do (82, 83, 91). However, the very high numbers of iNKT cells (~60% among CD4 T cells) reported by Akbari et al. have not been replicated by other investigators.

In contrast, a similar study by other group found that the number of iNKT cells was not increased in patients with asthma (91). Another group reported that iNKT cells were found in low numbers in the sputum or BALF of patients with asthma, chronic obstructive pulmonary disease and healthy controls, with no significant differences among the three groups (84). Mutalithas et al. also reported similar results in the BALF (85).
### TABLE 1
InNKT cells in patients with asthma.

| Year | Frequency of InNKT cells are | References | Staining method | Sample | Type of patients | % of NKT |
|------|-------------------------------|------------|-----------------|--------|------------------|---------|
| 2006 | Increased compared to HCs     | Akbari et al. (81) | CD1d-restricted NKT cells | BALF | Healthy controls | 0.9% of CD3+ cells (mean) |
|      |                               |            |                  |        | Patients with asthma treated with corticosteroids | 73% of CD3+ cells (mean) |
|      |                               |            |                  |        | Patients with asthma not treated with corticosteroids | 72% of CD3+ cells (mean) |
|      | Decreased compared to HCs or comparable to HCs | Hamzaoui et al. (82) | CD56+ Vα24+ NKT cells | Sputum | Healthy controls | 0.09 ± 0.02% in sputum |
|      |                               |            |                  |        | Severe asthma | 0.82 ± 0.07% in sputum |
|      |                               |            |                  |        | Mild asthma | 0.07 ± 0.05% in sputum |
| 2007 |                               | Pham-Thi et al. (83) | CD1d-restricted NKT cells | BALF | Non-atopic controls | 0.116 ± 0.03% in T cells |
|      |                               |            |                  |        | Asthma | 0.435 ± 0.09% in T cells |

(Continued)
| Year | Increased compared to HCs | Decreased compared to HCs or comparable to HCs |
|------|---------------------------|-----------------------------------------------|
|      | Reference | Staining method | Sample | Type of patients | % of NKT | Reference | Staining method | Sample | Type of patients | % of NKT |
| 2009 | Matangkas-ombut et al. (85) | CD1d-restricted NKT cells | BALF | No asthma | 0.07–0.68% of CD3+ cells | 6B11+ NKT cells | Sputum | Control subjects | 0% of CD3+ cells | Data not shown |
|      | Matangkas-ombut et al. (85) | CD1d-restricted NKT cells | BALF | Well controlled asthma | 0.05–9.57% of CD3+ cells | 6B11+ NKT cells | Sputum | Control subjects | 0–0.8% of CD3+ cells | Data not shown |
|      | Matangkas-ombut et al. (85) | CD1d-restricted NKT cells | BALF | Severe asthma | 2.43–7.18% of CD3+ cells | 6B11+ NKT cells | Sputum | Data not shown | 0 or 0.3% of CD3+ cells | Data not shown |
| 2010 | Brooks et al. (87) | 6B11+ NKT cells | Sputum | Controls | 0.12 ± 0.02% of CD3+ cells | 6B11+ NKT cells | BALF | Controls | 0% or 2.7% of CD3+ cells | Data not shown |

(Continued)
| Year | Increased compared to HCs | Decreased compared to HCs or comparable to HCs |
|------|---------------------------|-----------------------------------------------|
| Ref  | Staining method | Sample | Type of patients | % of NKT | Reference | Staining method | Sample | Type of patients | % of NKT |
| Koh et al. (88) | CD56^+ NKT cells | Sputum | Controls | 0.005 ± 0.005% in CD3^+ cells | Koh et al. (88) | CD56^+ NKT cells | PBMCs | Controls | 1.81 ± 0.33% in CD3^+ cells |
| | | Asthma | | 0.27 ± 0.08% in CD3^+ cells | | Asthma | | | 1.98 ± 0.37% in CD3^+ cells |
| | 6B11^+ NKT cells | Sputum | Controls | 0.32 ± 0.15% in CD3^+ cells | | 6B11^+ NKT cells | PBMCs | Controls | 0.22 ± 0.05% in CD3^+ cells |
| | | Asthma | | 0.76 ± 0.3% in CD3^+ cells | | Asthma | | | 0.24 ± 0.04% in CD3^+ cells |
| | Vα24^+ NKT cells | Sputum | Controls | 0.03 ± 0.02% in CD3^+ cells | | Vα24^+ NKT cells | PBMCs | Controls | 0.42 ± 0.05% in CD3^+ cells |
| | | Asthma | | 0.14 ± 0.03% in CD3^+ cells | | Asthma | | | 0.48 ± 0.04% in CD3^+ cells |
| 2012 | Yan-Ming et al. (89) | Vα24^+ Vβ11^+ NKT cells | PBMCs | Controls | Yan-Ming et al. (89) | Vα24^+ Vβ11^+ NKT cells | Controls | | 0.135 ± 0.061% in blood |
| | | Asthma | | 0.051 ± 0.041% in blood | | Asthma | | | |
| 2014 | Shim et al. (90) | Vα24^+ Vβ11^+ NKT cells | PBMCs | Controls | Shim et al. (90) | Vα24^+ Vβ11^+ NKT cells | PBMCs | Controls | 0.2 ± 0.1% in blood |
| | | Asthma | | 0.2 ± 0.2% in blood | | 6B11^+ Vβ12^+ NKT cells | PBMCs | Controls | 0.07 ± 0.01% in blood |
| | | Asthma | | 0.2 ± 0.1% in blood | | Asthma | | | |

BALF: bronchoalveolar lavage fluid; PBMCs, peripheral blood mononuclear cells; HCs, healthy controls.
Furthermore, the influx of iNKT cells in the airways was not observed after segmental allergen challenge (92, 93). To explain this discrepancy, Thomas et al. (93) and Vijayanand (84) pointed out that 6B11 antibody was able to stain alveolar macrophages nonspecifically. They suggested that the higher frequency of iNKT cells was due to the non-specific binding to the cells, and that the lymphocyte population should be gated for the analysis of iNKT cells (83, 91). However, Akbari et al. argued that they had already gated the lymphocyte population and used a CD1d-tetramer instead of 6B11 antibody to stain iNKT cells. In addition, those authors readdressed the issue regarding the number of iNKT cells in BALF from patients with severe asthma the next year (86). They confirmed that patients with severe asthma had a significantly increased number of iNKT cells compared to healthy controls. In this report, however, CD1d-restricted iNKT cells accounted for 2–7% of total CD3+ cells in the BALF of asthmatic patients, and only 1 patient with severe asthma had an iNKT cell proportion of 64.5% (93). The findings of Reynolds et al. supported the increase in the number of iNKT cells in the lung using biopsies with allergen challenge (94). Nevertheless Brooks et al. subsequently suggested that the high frequency of iNKT cells detected in BALF was due to the non-specific staining of dead cells (87). In addition, they also indicated that there was no marked difference in the frequency of 6B11+ iNKT cells in sputum even when including dead cells in the samples.

After 2010, it was suggested that a reduced iNKT cell frequency in the PBMCs of asthmatic patients did not imply that iNKT cells were irrelevant to the development of asthma. Koh et al. showed that the numbers of NKT cells in peripheral blood did not differ markedly between patients and control groups (88). However, in sputum, the numbers of iNKT cells were significantly increased in patients with asthma. Their subsequent study demonstrated the negative correlation between blood iNKT cell number and eosinophils, cytokines, or chemokines in sputum (95). These results suggested that iNKT cell might be mobilized to the lung during the exacerbation. Two other groups also demonstrated the profound reduction or no increase in iNKT cells in the blood of asthma patients compared to the normal control group (89, 90). However, they also showed an increased IL-4 production in iNKT cells of asthma patients compared to controls. Pedroza showed that pediatric asthmatic patients undergoing exacerbations of asthma displayed increased numbers of iNKT cells in the blood that also produced less IFN-γ and more IL-4 than children with stable asthma or in healthy control children (96). These results suggest that Th2-like iNKT cells might be involved in the development of asthmatic exacerbations.

At present, studies on iNKT cells in asthma patients have provided conflicting results. The frequency of iNKT cells in the lungs is particularly hotly debated. As such, we conclude that the frequency of iNKT cell does not always reflect the severity of the diseases. Although there are some recent reports that suggest no correlation between the blood iNKT cell number and clinical asthma severity (97), it is becoming more widely recognized that iNKT cells likely play a role in the development and possibly exacerbation of allergic asthma. In addition, the studies of iNKT cells in other asthma etiologies, such as chronic, occupational, steroid-resistant, exercise-induced, and aspirin-induced asthma, where Th2 cells may not play a major role, may provide new insights into these type of diseases. We therefore suggest a few experimental design approaches to adopt when studying the role of iNKT cells in particular diseases. First, in the flow cytometry analysis of iNKT cells in patients, lymphocytes, particularly live cells, should be gated for the analysis, and control staining, including with isotype controls, should be performed, with the results compared. This will prevent the contamination of cells with non-specific staining patterns. Second, more than two staining protocol should be employed. At least three different approaches have been established for identifying iNKT cells, such as CD1d-tetramer, anti-Vα24 antibody and 6B11 antibody recognizing the CDR3 region of Vα24-JαQ TCR. Although these approaches should theoretically provide similar results, using multiple staining protocols may help clear up any confusion if controversial results are obtained. Third, in addition to assessing the frequency of iNKT cells, their cytokine production (IL-2, IL-4, IFN-γ, or IL-17) should also be examined by flow cytometry. As we discussed above, it would be difficult to demonstrate the relevance of iNKT cells to diseases by analyzing only the frequency of such a small population. Examining changes in their function may therefore be useful for elucidating their contribution to the pathology of diseases.

MR1-RESTRICTED CELLS

MAIT cells are a subset of innate-like T lymphocytes first described in 1999 (98). These MR-1-restricted cells are abundant in humans and can rapidly express a variety of pro-inflammatory cytokines (12). While iNKT cells are suggested to play critical roles in murine models of allergic airway diseases, they are rare in human airways. MAIT cells, by contrast, are 5- to 10-fold more abundant in humans than in mice (15). Since MAIT cells exist in the lung and may be able to produce Th2 cytokines (19, 20), these cells may contribute to the development of asthma. However, several reports have indicated a different role for these cells. Hinks et al. observed a striking deficiency of Vα7.2+ CD161+ T cells in blood, sputum, and bronchial biopsy samples, suggesting that the deficiency correlated with the severity of asthma (11, 99). A similar deficiency in humans was observed in autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis, Crohn’s disease, ulcerative colitis, or chronic inflammatory disease, such as type 2 diabetes) (100–103). In addition, it was reported that an increased MAIT cell frequency at 1 year of age was associated with a decreased risk of asthma by 7 years of age (104). These results suggest that MAIT cells may play a protective role against chronic inflammation.

Given that MAIT cells respond to bacterial metabolites, it is possible that MAIT cell activation by gut or lung microbiota is required to prevent asthma. If MAIT cells can exert a suppressive function against chronic inflammation, this hypothesis would be inconsistent with their ability to produce various inflammatory cytokines. In addition, it was also reported that the numbers of MAIT cells producing IL-17 are increased in asthmatic
patients (105). Since MAIT-deficient mice have been generated (106), investigations into the function of MAIT cells infiltrating the inflammatory site in mouse models may help provide answers.

CONCLUSION

Studies investigating the roles of iNKT cells in allergic responses have helped to explain the Th2-dependent mechanisms underlying the development of allergic asthma. However, iNKT cells also have been suggested to be associated with the development of non-allergic airway inflammation that is induced and/or exacerbated by non-Th2 factors, such as viruses, air pollution and inflammatory cytokines (IL-17 or TNFα). Furthermore, recent studies have suggested that NKT cells or MAIT cells may play a critical role in the inhibition of asthmatic symptoms. Although a clear conclusion has not been reached due to inconsistent results, innate-like T cells apparently have critical and varied roles in regulating immune responses. As such, more intensive studies will be required in order to elucidate the mechanisms underlying the induction of various types of asthma by innate-like T cells and establish innovative therapeutic strategies.

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

FUNDING

Grants-in-Aid for Scientific Research (S) (TN#26221305), the Practical Research Project for Allergic Diseases and Immunology (Research on Allergic Diseases and Immunology) from Japan Agency for Medical Research and development, AMED (JP18ek0410030) (TN).

REFERENCES

1. Godfrey DI, Ulrich AP, Mccluskey J, Rossjohn J, Moody DB. The burgeoning family of unconventional T cells. Nat Immunol. (2015) 16:1114–23. doi: 10.1038/nj.3298
2. Cohen NR, Garg S, Brenner MB. Antigen presentation by CD1 lipids, T cells, and NKT cells in microbial immunity. Adv Immunol. (2009) 102:1–94. doi: 10.1016/S0065-2776(09)01201-2
3. Berzins SP, Smyth MJ, Baxter AG. Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol. (2011) 11:131–42. doi: 10.1038/nri2904
4. Van Kaer L, Parekh VV, Wu L. The Response of CD1d- Restricted Invariant NKT cells to microbial pathogens and their products. Front Immunol. (2015) 6:226. doi: 10.3389/fimmu.2015.00226
5. Iwamura C, Nakayama T. Role of NKT cells in allergic asthma. Curr Opin Immunol. (2010) 22:807–13. doi: 10.1016/j.coi.2010.10.008
6. Wu L, Van Kaer L. Natural killer T cells and autoimmune disease. Curr Mol Med. (2009) 9:4–14. doi: 10.2174/156652409787314534
7. Moro L, Lepore M, De Liber G. The Immunology of CD1- and MR1-Restricted T Cells. Annu Rev Immunol. (2016) 34:479–510. doi: 10.1146/annurev-immunol-032414-112008
8. Kjer-Nielsen L, Patel O, Corbett AJ, Le Nours J, Meehan B, Liu L, et al. MR1 presents microbial vitamin B metabolites to MAIT cells. Nature. (2012) 491:717–23. doi: 10.1038/nature11605
9. Constantinides MG. Interactions between the microbiota and innate and innate-like lymphocytes. J Leukoc Biol. (2018) 103:409–19. doi: 10.1002/JLB.3R1017-378R
10. Ghaazarian L, Caillat-Zucman S, Houdouin V. Mucosal-associated invariant T cell interactions with commensal and pathogenic bacteria: potential role in antimicrobial immunity in the child. Front Immunol. (2017) 8:1837. doi: 10.3389/fimmu.2017.01837
11. Hinks TS. Mucosal-associated invariant T cells in autoimmunity, immune-mediated diseases and airways disease. Immunology (2016) 148:1–12. doi: 10.1111/imm.12582
12. Fan X, Rudensky AY. Hallmarks of tissue-resident lymphocytes. Cell. (2016) 164:1198–211. doi: 10.1016/j.cell.2016.02.048
13. Gold MC, Lewinsohn DM. Mucosal associated invariant T cells and the immune response to infection. Microbes Infect. (2011) 13:742–8. doi: 10.1016/j.micinf.2011.03.007
14. Slauenwhite D, Johnston B. Regulation of NKT Cell Localization in Homeostasis and Infection. Front Immunol. (2015) 6:255. doi: 10.3389/fimmu.2015.00255
15. Treiner E, Duban L, Moura IC, Hansen T, Gillilam S, Lantz O. Mucosal-associated invariant T (MAIT) cells: an evolutionarily conserved T cell subset. Microbes Infect. (2005) 7:552–9. doi: 10.1016/j.micinf.2004.12.013
16. Brennan PJ, Brigl M, Brenner MB. Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat Rev Immunol. (2013) 13:101–17. doi: 10.1038/nri3369
17. Lee YJ, Holzapfel KL, Zhu J, Jameson SC, Hogquist KA. Steady-state production of IL-4 modulates immunity in mouse strains and is determined by lineage diversity of iNKT cells. Nat Immunol. (2013) 14:1146–54. doi: 10.1038/ni.2731
18. Watarai H, Sekine-Kondo E, Shigeura T, Motomura Y, Yasuda T, Satoh R, et al. Development and function of invariant natural killer T cells producing T(h)2- and T(h)17-cytokines. PLoS Biol. (2012) 10:e1001255. doi: 10.1371/journal.pbio.1001255
19. Lee OJ, Cho YN, Kee SJ, Kim MJ, Jin HM, Lee SJ, et al. Circulating mucosal-associated invariant T cell levels and their cytokine levels in healthy adults. Exp Gerontol. (2014) 49:47–54. doi: 10.1016/j.exger.2013.11.003
20. Lepore M, Kalinichenko A, Coloné A, Paleja B, Singhal A, Tschumi A, et al. Parallel T-cell cloning and deep sequencing of human MAIT cells reveal stable oligoclonal TCRβeta repertoire. Nat Commun. (2014) 5:3866. doi: 10.1038/ncomms4866
21. Locksley RM. Asthma and allergic inflammation. Cell. (2010) 140:777–83. doi: 10.1016/j.cell.2010.03.004
22. Endo Y, Hirahara K, Inuma T, Shinoda K, Tumes DJ, Asou HK, et al. The interleukin-33-p38 kinase axis confers memory T helper 2 cell pathogenicity in the airway. Immunity (2015) 42:294–308. doi: 10.1016/j.immuni.2015.01.016
23. Mitson-Salazar A, Yin Y, Wansley DL, Young M, Bolan H, Arceo S, et al. Hematopoietic prostaglandin D synthase defines a proeosinophilic pathogenic effector human T(H)2 cell subset with enhanced function. J Allergy Clin Immunol. (2016) 137:907–18 e9. doi: 10.1016/j.jaci.2015.08.007
24. Nakayama T, Hirahara K, Onodera A, Endo Y, Hosokawa H, Shinoda K, et al. Th2 Cells in Health and Disease. Annu Rev Immunol. (2017) 35:53–84. doi: 10.1146/annurev-immunol-051116-052350
25. Wambre B, Bajzik V, Delong JH, O`brien K, Nguyen QA, Speake C, et al. A phenotypically and functionally distinct human TH2 cell subpopulation is associated with allergic disorders. Sci Transl Med. (2017) 9:do: 10.1126/scitranslmed.aam9171
26. Lefrancois L. Development, trafficking, and function of memory T-cell subsets. Immunol Rev. (2006) 211:93–103. doi: 10.1111/j.0105-2896.2006.00393.x
27. Shinoda K, Hirahara K, Nakayama T. Maintenance of pathogenic Th2 cells in allergic disorders. *Allergol Int.* (2017) 66:369–76. doi: 10.1016/j.alit.2017.03.005

28. Morimoto Y, Hirahara K, Kiuchi M, Wada T, Ichikawa T, Kanno T, et al. Amphiregulin-producing pathogenic memory T helper 2 cells instruct eosinophilic to secrete granulopeptid and facilitate airway fibrosis. *Immunity* (2018) 49:134–50 e6. doi: 10.1016/j.immuni.2018.04.023

29. Kim HY, Dekruyff RH, Umetsu DT. The many paths to asthma: phenotype shaped by innate and adaptive immunity. *Nat Immunol.* (2010) 11:577–84. doi: 10.1038/ni.1892

30. Akbari O, Stock P, Meyer E, Kronenberg M, Sidobre S, Nakayama T, et al. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. *Nat Med.* (2003) 9:582–8. doi: 10.1038/nm581

31. Koh YI, Kim HY, Meyer EH, Pichavant M, Akbari O, Yasumi T, et al. Activation of nonclassical CD1d-restricted NK T cells induces airway hyperreactivity in beta 2-microglobulin-deficient mice. *J Immunol.* (2008) 181:4560–9. doi: 10.4049/jimmunol.181.7.4560

32. Woo YD, Koh J, Kang HR, Kim HY, Chung DH. The invariant natural killer T cell-mediated chemokine X-C motif chemokine ligand 1-X-C motif chemokine receptor 1 axis promotes allergic airway hyperresponsiveness by recruiting CD103(+)/dendritic cells. *J Allergy Clin Immunol.* (2018) doi: 10.1016/j.jaci.2017.12.005

33. Nie H, Yang Q, Zhang G, Wang A, He Q, Liu M, et al. Invariant NKT cells act as an adjuvant to enhance Th2 cytokine response in allergic inflammation in a OVA-induced mouse model of asthma. *PLoS ONE* (2015) 10:e0119901. doi: 10.1371/journal.pone.0119901

34. Das J, Eynott P, Jupp R, Bothwell A, Van Kaer L, Shi Y, et al. Natural killer T cells are dispensable for T cell-dependent allergic airway inflammation. *Nat Med.* (2006) 12:1345–6. doi: 10.1038/nm1206-1345

35. Mcknight CG, Morris SC, Perkins C, Zhu Z, Hildeman D, Bendelac A, et al. NKT cells contribute to basal IL-4 production but are not required to induce experimental asthma. *PLoS ONE* (2012) 17:e0188221. doi: 10.1371/journal.pone.0188221

36. Hachem P, Lisboine M, Michel ML, Diem S, Roongapinun S, Lefort I, et al. Alpha-galactosylceramide-induced iNKT cells suppress experimental allergic asthma in sensitized mice: role of IFN-gamma. *Eur J Immunol.* (2005) 35:2793–802. doi: 10.1002/eji.200535268

37. Matsuda H, Takeda K, Koya T, Okamoto M, Shiraishi Y, Miyahara N, et al. Plasticity of invariant NKT cell regulation of allergic airway disease is dependent on IFN-gamma production and IL-4. *J Immunol.* (2010) 185:253–62. doi: 10.4049/jimmunol.0902301

38. Grela E, Aumeunier A, Bardele E, Van LP, Bourgeois E, Vanoiebræk J, et al. The TLR7 agonist R848 alleviates allergic inflammation by targeting invariant NKT cells to produce IFN-gamma. *J Immunol.* (2011) 186:284–90. doi: 10.4049/jimmunol.1001348

39. Endo Y, Hirahara K, Yagi R, Tumes DJ, Nakayama T. Pathogenic memory type Th2 cells in allergic inflammation. *Trends Immunol.* (2014) 35:69–78. doi: 10.1016/j.ti.2013.11.003

40. Iwamura C, Shinoda K, Endo Y, Watanabe Y, Tumes DJ, Motohashi S, et al. Regulation of memory CD4 T-cell pool size and function by natural killer T cells in vivo. *Proc Natl Acad Sci USA.* (2012) 109:16992–7. doi: 10.1073/pnas.1203494109

41. Chang YI, Kim HY, Albacker LA, Lee HH, Baumgart H, Akira S, et al. Influenza infection in suckling mice expands an NKT cell subset that is dependent on IFN-gamma production. *J Immunol.* (2010) 185:5225–35. doi: 10.4049/jimmunol.0902301

42. Segawa K, Nagata S. An apoptotic ‘eat me’ signal: phosphatidylserine receptors that regulate innate and adaptive immunity. *Nat Rev Immunol.* (2009) 9:577–90. doi: 10.1038/nri2559

43. Kim HY, Dekruyff RH, Umetsu DT. Crucial role for CD69 in allergic inflammatory responses: CD69-Myl9 system in the pathogenesis of airway inflammation. *Immunity* (2017) 278:87–100. doi: 10.1111/imr.12559

44. Tupin E, Kinjo Y, Kronenberg M. The unique role of natural killer T cells in the response to microorganisms. *Nat Rev Microbiol.* (2007) 5:405–17. doi: 10.1038/nrmicro1657

45. Kim EY, Battaele JT, Patel AC, You Y, Agapov E, Grayson MH, et al. Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. *Nat Med.* (2008) 14:633–40. doi: 10.1038/nm1770

46. O’connor G T, Walter M, Hearne PQ, Kerr K, Finkbeiner WE, Balmes JR, et al. Airway epithelial cell death in urban communities: The Inner-City Asthma Study. *J Allergy Clin Immunol.* (2004) 114:599–606. doi: 10.1016/j.jaci.2004.05.064

47. Albacker LA, Chaudhary V, Chang YJ, Kim HY, Chuang YT, Pichavant M, et al. Invariant natural killer T cells recognize a fungal glycosphingolipid that can induce airway hyperreactivity. *Nat Med.* (2013) 19:1297–304. doi: 10.1038/nm.3231

48. Wingender G, Rogers P, Batzger G, Lee MS, Rai D, Pei B, et al. Invariant NKT cells are required for airway inflammation induced by environmental antigens. *J Exp Med.* (2011) 208:1151–62. doi: 10.1084/jem.20102229

49. Aris RM, Christian D, Hearne PQ, Kerr K, Finkbeiner WE, Balmes JR. Ozone-induced airway inflammation in human subjects as determined by airway lavage and biopsy. *Am Rev Respir Dis.* (1993) 148:1363–72.

50. Murphy SR, Oslund KL, Hyde DM, Miller LA, Van Winkle LS, Schelegle ES. Ozone-induced airway epithelial cell death, the neurokinin-1 receptor pathway, and the postnatal developing lung. *Am J Physiol Lung Cell Mol Physiol.* (2014) 307:L471–81. doi: 10.1152/ajplung.00347.2013

51. Pichavant M, Goya S, Meyer EH, Johnston RA, Kim HY, Bu X, et al. Ozone exposure in a mouse model induces airway hyperreactivity that requires the presence of natural killer T cells and IL-17. *J Exp Med.* (2008) 205:385–93. doi: 10.1084/jem.20071507

52. Freeman GJ, Casasnovas JM, Umetsu DT, Dekruyff RH. TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. *Immunity* (2010) 32:172–89. doi: 10.1016/j.immuni.2010.09.003.x

53. Segawa K, Nagata S. An apoptotic ‘eat me’ signal: phosphatidylserine exposure. *Trends Cell Biol.* (2015) 25:639–50. doi: 10.1016/j.tcb.2015.08.003

54. Pok+F(ETC) promotes the production of IL-17A by murine CD1d-driven invariant NKT cells in airway inflammation. *Allergy* (2012) 67:1223–32. doi: 10.1111/j.1398-9995.2012.02876.x

55. Barrett NA, Austen KF. In innate cells and T helper 2 cell immunity in airway inflammation. *Immunity* (2009) 3:425–37. doi: 10.1016/j.immuni.2009.08.014
Iwamura and Nakayama Innate Like-T Cells in Asthma

63. Xu M, Dong C. IL-25 in allergic inflammation. *Immunol Rev.* (2017) 278:185–91. doi: 10.1111/imr.12558

64. Stock P, Lombardi V, Kohrlautz V, Akbari O. Induction of airway hyperreactivity by IL-25 is dependent on a subset of invariant NKT cells expressing IL-17RB. *J Immunol.* (2009) 182:5116–22. doi: 10.4049/jimmunol.08004213

65. Terashima A, Watarai H, Inoue S, Sekine E, Nakagawa R, Hase K, et al. A novel subset of mouse NKT cells bearing the IL-17 receptor B responds to IL-25 and contributes to airway hyperreactivity. *J Exp. Med.* (2008) 205:2727–33. doi: 10.1084/jem.20080698

66. Cianfaroni A, Spergel J. The importance of TSLP in allergic disease and its role as a potential therapeutic target. *Expert Rev Clin Immunol.* (2014) 10:1463–74. doi: 10.1586/1744666X.2014.967684

67. Nagata Y, Kamijuku H, Taniguchi M, Ziegler S, Seino K. Differential role of thymic stromal lymphopoietin in the induction of airway hyperreactivity and Th2 immune response in antigen-induced asthma with respect to natural killer T cell function. *Int Arch Allergy Immunol.* (2007) 144:305–14. doi: 10.1159/000106319

68. Bourgeois E, Van LP, Samson M, Diem S, Barra A, Roga S, et al. The role of thymic stromal lymphopoietin in the induction of airway hyperreactivity and Th2 immune response in antigen-induced asthma with respect to natural killer T cell function. *Int Arch Allergy Immunol.* (2007) 144:305–14. doi: 10.1159/000106319

69. Smithgall MD, Comeau MR, Yoon BR, Kaufman D, Armitage R, Smith M, et al. Induction of airway inflammation and hyperreactivity in an experimental asthma model. *Immunol Rev.* (2010) 184:2107–15. doi: 10.4049/jimmunol.0901208

70. Akbari O, Faul JL, Hoyte EG, Berry GJ, Wahlstrom J, Kronenberg M, et al. CD4+ invariant T-cell receptor+ natural killer T cells in bronchial asthma. *N Engl J Med.* (2006) 354:1117–29. doi: 10.1056/NEJMoa053614

71. Lundblad LKA, Gulec N, Poynter ME, Devault VL, Dienz O, Boyson J, et al. Mouse invariant monoclonal antibody NKT14: a novel tool to manipulate iNKT cell function in vivo. *PLoS ONE* (2015) 10:e0140729. doi: 10.1371/journal.pone.0140729

72. Pham-Thi N, De Blic J, Le Bourgeois M, Dy M, Scheinmann P, Leite-De-Moraes MC. Enhanced frequency of immunoregulatory invariant natural killer T cells in the airways of children with asthma. *J Allergy Clin Immunol.* (2006) 117:217–8. doi: 10.1016/j.jaci.2005.09.052

73. Muttilithas K, Croudcace J, Guillon C, Siddiqui S, Thickett D, Wardlaw A, et al. Bronchoalveolar lavage invariant natural killer T cells are not increased in asthma. *J Allergy Clin Immunol.* (2011) 127:1274–6. doi: 10.1016/j.jaci.2007.02.021

74. Matangkasombat P, Marigowda G, Ervine A, Idris L, Pichavant M, Kim HY, et al. Natural killer T cells in the lungs of patients with asthma. *J Allergy Clin Immunol.* (2009) 123:1181–5. doi: 10.1016/j.jaci.2009.02.013

75. Brooks CR, Weinkove R, Hermans IF, Van Dalen CJ, Douwes J. Invariant natural killer T cells and asthma: immunologic reality or methodologic artifact? *J Allergy Clin Immunol.* (2010) 126:882–5. doi: 10.1016/j.jaci.2010.06.041

76. Koh YI, Shim JU. Association between sputum natural killer T cells and eosinophilic airway inflammation in human asthma. *Int Arch Allergy Immunol.* (2010) 153:239–48. doi: 10.1159/000301436

77. Yan-Ming L, Lan-Fang C, Chen L, Ya-Qin L, Wei C, Wen-Ming Z. The effect of specific immunotherapy on natural killer T cells in peripheral blood of house dust mite-sensitized children with asthma. *Clin Dev Immunol.* (2012) 2012:148262. doi: 10.1155/2012/148262

78. Shim JU, Koh YI. Increased Th2-like invariant natural killer T cells in peripheral blood from patients with asthma. *Asthma Allergy Immune Res.* (2014) 6:444–8. doi: 10.4168/air.2014.6.5.444

79. Thomas SY, Lilly CM, Luster AD. Invariant natural killer T cells in bronchial asthma. *N Engl J Med.* (2006) 354:2613–6. doi: 10.1056/NEJMoa061689

80. Bratke K, Julius P, Virchow JC. Invariant natural killer T cells in obstructive pulmonary diseases. *N Engl J Med.* (2007) 357:199–204. doi: 10.1056/NEJMmc067162

81. Thomas SY, Banerji A, Medoff BD, Lilly CM, Luster AD. Multiple chemokine receptors, including CCR6 and CXCR3, regulate antigen-induced T cell homing to the human asthmatic airway. *J Immunol.* (2007) 179:1901–12. doi: 10.4049/jimmunol.179.3.1901

82. Reynolds C, Barkans J, Clark P, Kariyawasam H, Altman D, Kay B, et al. Natural killer T cells in bronchial biopsies from human allergen challenge model of allergic asthma. *J Allergy Clin Immunol.* (2009) 124:860–2. doi: 10.1016/j.jaci.2009.07.022

83. Koh YI, Shim JU, Wi J, Kwon YE. The role of natural killer T cells in the pathogenesis of acute exacerbation of human asthma. *Int Arch Allergy Immunol.* (2012) 158:131–41. doi: 10.1159/000330908

84. Carpio-Pedroza JC, Vaughan G, Del Rio-Navarro BE, Del Rio-Chivaridi JM, Vergara-Castaneda A, Jimenez-Zamudio LA, et al. Participation of CD1d(+) and invariant natural killer T cells in pediatric asthma exacerbations. *Allergy Asthma Proc.* (2013) 34:84–92. doi: 10.2500/aap.2013.34.3619

85. Zedan MM, El-Chennawi FA, Fouda AE. Interleukin-12 and peripheral blood invariant natural killer T cells as an axis in childhood asthma pathogenesis. *Iran J Allergy Asthma Immunol.* (2010) 9:43–8.

86. Tilloy F, Treiner E, Park SH, Garcia C, Lemonnier F, De La Salle H, et al. An invariant T cell receptor alpha chain defines a novel TAP-independent major histocompatibility class Ib-restricted alpha/beta T cell subpopulation in mammals. *J Exp. Med.* (1999) 189:1907–21.

87. Hinks TS, Zhou X, Staples KJ, Dimitrov BD, Manta A, Petrotssian T, et al. Innate and adaptive T cells in asthmatic patients: relationship to severity and disease mechanisms. *J Allergy Clin Immunol.* (2015) 136:323–33. doi: 10.1016/j.jaci.2015.01.014
100. Cho YN, Kee SJ, Kim TJ, Jin HM, Kim MJ, Jung HJ, et al. Mucosal-associated invariant T cell deficiency in systemic lupus erythematosus. *J Immunol.* (2014) 193:3891–901. doi: 10.4049/jimmunol.1302701

101. Hiejima E, Kawai T, Nakase H, Tsuruyama T, Morimoto T, Yasumi T, et al. Reduced numbers and proapoptotic features of mucosal-associated invariant T cells as a characteristic finding in patients with inflammatory bowel disease. *Inflamm Bowel Dis.* (2015) 21:1529–40. doi: 10.1097/MIB.0000000000000397

102. Magalhaes I, Pingris K, Poitou C, Bessoles S, Venteclef N, Kiaf B, et al. Mucosal-associated invariant T cell alterations in obese and type 2 diabetic patients. *J Clin Invest.* (2015) 125:1752–62. doi: 10.1172/JCI78941

103. Serriari NE, Eoche M, Lamotte L, Lion J, Fumery M, Marcelo P, et al. Innate mucosal-associated invariant T (MAIT) cells are activated in inflammatory bowel diseases. *Clin Exp Immunol.* (2014) 176:266–74. doi: 10.1111/cei.12277

104. Chandra S, Wingender G, Greenbaum JA, Khurana A, Gholami AM, Ganesan AP, et al. Development of asthma in inner-city children: possible roles of MAIT cells and variation in the home environment. *J Immunol.* (2018) 200:1995–2003. doi: 10.4049/jimmunol.1701525

105. Lezmi G, Abou Taam R, Dietrich C, Chatenoud L, De Blie De-Moraes M. Circulating IL-17-producing mucosal-associated invariant T cells (MAIT) are associated with symptoms in children with asthma. *Clin Immunol.* (2017) 188:7–11. doi: 10.1016/j.clim.2017.11.009

106. Kawachi I, Maldonado J, Strader C, Gilfillan S. MR1-restricted V alpha 19i mucosal-associated invariant T cells are innate T cells in the gut lamina propria that provide a rapid and diverse cytokine response. *J Immunol.* (2006) 176:1618–27. doi: 10.4049/jimmunol.176.3.1618

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Iwamura and Nakayama. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.